Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Mease

Showing results (81-90 of 174) with videos related to

Pageof 18
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|July 4, 2015
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging studyMichael E Weinblatt, Philip Mease, Eduardo Mysler, et al.
ACR Open Rheumatology|October 19, 2020
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT StudyPhilip Mease, M Elaine Husni, Soumya D Chakravarty, et al.
Journal of Comparative Effectiveness Research|February 27, 2019
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritisVibeke Strand, Iain McInnes, Philip Mease, et al.
Pain Medicine (Malden, Mass.)|June 14, 2013
Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections studyRebecca L Robinson, Kurt Kroenke, David A Williams, et al.
Current Medical Research and Opinion|August 18, 2022
Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trialsPhilip Mease, Louis Kuritzky, Wendy L Wright, et al.
Arthritis Care & Research|May 14, 2013
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trialArthur Kavanaugh, Iain B McInnes, Gerald G Krueger, et al.
The Clinical Journal of Pain|February 1, 2014
Long-term evaluation of opioid treatment in fibromyalgiaXiaomei Peng, Rebecca L Robinson, Philip Mease, et al.
Arthritis Care & Research|August 30, 2018
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical TrialsPhilip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, et al.
RMD Open|June 29, 2026
Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature reviewDafne Capelusnik, Clementina López-Medina, Casper Weber, et al.
Arthritis Research & Therapy|March 8, 2020
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trialPhilip Mease, M Elaine Husni, Shelly Kafka, et al.
Pageof 18

Showing results (81-90 of 174) with videos related to

Sort By:
Pageof 18
Arthritis & Rheumatology (Hoboken, N.J.)|July 4, 2015
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging studyMichael E Weinblatt, Philip Mease, Eduardo Mysler, et al.
ACR Open Rheumatology|October 19, 2020
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT StudyPhilip Mease, M Elaine Husni, Soumya D Chakravarty, et al.
Journal of Comparative Effectiveness Research|February 27, 2019
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritisVibeke Strand, Iain McInnes, Philip Mease, et al.
Pain Medicine (Malden, Mass.)|June 14, 2013
Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections studyRebecca L Robinson, Kurt Kroenke, David A Williams, et al.
Current Medical Research and Opinion|August 18, 2022
Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trialsPhilip Mease, Louis Kuritzky, Wendy L Wright, et al.
Arthritis Care & Research|May 14, 2013
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trialArthur Kavanaugh, Iain B McInnes, Gerald G Krueger, et al.
The Clinical Journal of Pain|February 1, 2014
Long-term evaluation of opioid treatment in fibromyalgiaXiaomei Peng, Rebecca L Robinson, Philip Mease, et al.
Arthritis Care & Research|August 30, 2018
Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical TrialsPhilip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, et al.
RMD Open|June 29, 2026
Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature reviewDafne Capelusnik, Clementina López-Medina, Casper Weber, et al.
Arthritis Research & Therapy|March 8, 2020
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trialPhilip Mease, M Elaine Husni, Shelly Kafka, et al.
Pageof 18